These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

601 related items for PubMed ID: 30346636

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study.
    Romano M, Gravina AG, Nardone G, Federico A, Dallio M, Martorano M, Mucherino C, Romiti A, Avallone L, Granata L, Priadko K, Compare D, Tuccillo C, Romito MR, Sgambato D, Miranda A, Romano L, Loguercio C, Bazzoli F, Zagari RM.
    Helicobacter; 2020 Aug; 25(4):e12694. PubMed ID: 32314519
    [Abstract] [Full Text] [Related]

  • 3. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg).
    Nyssen OP, Perez-Aisa A, Rodrigo L, Castro M, Mata Romero P, Ortuño J, Barrio J, Huguet JM, Modollel I, Alcaide N, Lucendo A, Calvet X, Perona M, Gomez B, Gomez Rodriguez BJ, Varela P, Jimenez-Moreno M, Dominguez-Cajal M, Pozzati L, Burgos D, Bujanda L, Hinojosa J, Molina-Infante J, Di Maira T, Ferrer L, Fernández-Salazar L, Figuerola A, Tito L, de la Coba C, Gomez-Camarero J, Fernandez N, Caldas M, Garre A, Resina E, Puig I, O'Morain C, Megraud F, Gisbert JP.
    Helicobacter; 2020 Oct; 25(5):e12722. PubMed ID: 32656898
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of three-in-one capsule bismuth quadruple therapy for Helicobacter pylori eradication in clinical practice in a multinational patient population.
    Miehlke S, Frederking D, Günther T, Glocker E, Eisele B, Andresen V, Schröder S, Morgner A.
    Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28833925
    [Abstract] [Full Text] [Related]

  • 5. The "three-in-one" formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice.
    Zagari RM, Romiti A, Ierardi E, Gravina AG, Panarese A, Grande G, Savarino E, Maconi G, Stasi E, Eusebi LH, Farinati F, Conigliaro R, Bazzoli F, Romano M.
    Helicobacter; 2018 Aug; 23(4):e12502. PubMed ID: 29924430
    [Abstract] [Full Text] [Related]

  • 6. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.
    Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P.
    Digestion; 2013 Aug; 88(1):33-45. PubMed ID: 23880479
    [Abstract] [Full Text] [Related]

  • 7. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, Chen MJ, Chen CC, Tseng CH, Hsu YC, Lee JY, Yang TH, Luo JC, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hu WH, Chen YN, Sheu BS, Lin JT, Wu JY, El-Omar EM, Wu MS, Taiwan Gastrointestinal Disease and Helicobacter Consortium.
    Lancet; 2016 Nov 12; 388(10058):2355-2365. PubMed ID: 27769562
    [Abstract] [Full Text] [Related]

  • 8. Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains.
    Fiorini G, Saracino IM, Zullo A, Gatta L, Pavoni M, Vaira D.
    Helicobacter; 2017 Dec 12; 22(6):. PubMed ID: 29094477
    [Abstract] [Full Text] [Related]

  • 9. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
    Tsay FW, Wu DC, Yu HC, Kao SS, Lin KH, Cheng JS, Wang HM, Chen WC, Sun WC, Tsai KW, Hsu PI.
    Antimicrob Agents Chemother; 2017 Nov 12; 61(11):. PubMed ID: 28807915
    [Abstract] [Full Text] [Related]

  • 10. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
    Lu B, Wang J, Li J, Liu L, Chen Y.
    Helicobacter; 2019 Apr 12; 24(2):e12566. PubMed ID: 30780194
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.
    Liang X, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, Xiao S, Lu H.
    Clin Gastroenterol Hepatol; 2013 Jul 12; 11(7):802-7.e1. PubMed ID: 23376004
    [Abstract] [Full Text] [Related]

  • 12. Comparison of Helicobacter pylori eradication rates between 7 and 14 days of tailored therapy according to clarithromycin resistance test: A randomized, multicenter, non-inferiority study.
    Jung K, Jee SR, Lee MW, Koh M, Kim SJ, Lee J, Park MI.
    Helicobacter; 2024 Jul 12; 29(3):e13084. PubMed ID: 38717034
    [Abstract] [Full Text] [Related]

  • 13. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q, Liang X, Zheng Q, Liu W, Xiao S, Gu W, Lu H.
    Helicobacter; 2010 Jun 12; 15(3):233-8. PubMed ID: 20557366
    [Abstract] [Full Text] [Related]

  • 14. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
    Lee JY, Kim N, Park KS, Kim HJ, Park SM, Baik GH, Shim KN, Oh JH, Choi SC, Kim SE, Kim WH, Park SY, Kim GH, Lee BE, Jo Y, Hong SJ.
    BMC Gastroenterol; 2016 Jul 26; 16(1):79. PubMed ID: 27460100
    [Abstract] [Full Text] [Related]

  • 15. Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children.
    Zhou Y, Ye Z, Wang Y, Zhang Y, Tang Z, Yan W, Jiang Y, Huang Y.
    Helicobacter; 2020 Apr 26; 25(2):e12679. PubMed ID: 31958193
    [Abstract] [Full Text] [Related]

  • 16. New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese prospective, randomized, multicentre trial.
    Xie Y, Pan X, Li Y, Wang H, Du Y, Xu J, Wang J, Zeng Z, Chen Y, Zhang G, Wu K, Liu D, Lv N.
    J Antimicrob Chemother; 2018 Jun 01; 73(6):1681-1687. PubMed ID: 29596646
    [Abstract] [Full Text] [Related]

  • 17. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
    Fiorini G, Zullo A, Saracino IM, Gatta L, Pavoni M, Vaira D.
    Eur J Gastroenterol Hepatol; 2018 Jun 01; 30(6):621-625. PubMed ID: 29481383
    [Abstract] [Full Text] [Related]

  • 18. Tailored therapy guided by genotypic resistance of clarithromycin and levofloxacin detected by polymerase chain reaction in the first-line treatment of Helicobacter pylori infection.
    Li CL, Zhou K, Zhang YX, Suo BJ, Tian XL, Zhang YX, Ren XL, Shi YY, Zhou LY, Song ZQ.
    J Dig Dis; 2024 Jan 01; 25(1):36-43. PubMed ID: 38323705
    [Abstract] [Full Text] [Related]

  • 19. A "new" option in Helicobacter pylori eradication: High-dose amoxicillin dual therapy outperforms bismuth quadruple therapy in a high dual resistance setting.
    Macedo Silva V, Lima Capela T, Freitas M, Boal Carvalho P, Magalhães J, Cotter J.
    Helicobacter; 2023 Jun 01; 28(3):e12962. PubMed ID: 36828647
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.